Johnson & Johnson (JNJ)
Exclusive: J&J near disclosing support for talc settlement, sources say
Johnson & Johnson is preparing to unveil widespread support in coming days for a $6.48 billion offer to settle tens of thousands of legal actions alleging its Baby Powder and other talc products caused cancer, two people familiar with the matter said.
3 Blue-Chip Stocks to Buy on the Dip: August 2024
Blue-chip stocks are commanding attention from investors looking for stability and reliability amidst a fluctuating market. Typically, these stock market stalwarts are known for their solid financials, long histories of profitability and consistent records of dividend payments.
J&J has enough support from claimants for $6.5 billion talc settlement: report
Johnson & Johnson is reportedly nearing enough support to finalize a $6.5 billion settlement for lawsuits related to cancer cases linked to its baby powder and other talc products.
J&J has enough support from claimants for $6.5 billion talc settlement - Bloomberg
Johnson & Johnson has cleared a key threshold of support for its proposed $6.5 billion settlement of tens of thousands of lawsuits alleging its baby powder and other talc products caused cancer, according to a Bloomberg report.
J&J's (JNJ) DePuy Synthes' TriLEAP System to Aid Ankle Surgery
Johnson & Johnson's (JNJ) DePuy Synthes announces the launch of its TriLEAP System, which is likely to provide better orthopedic solutions to foot and ankle surgeons.
2 Healthcare Stocks to Buy Hand Over Fist in August
Eli Lilly is a leader in diabetes and obesity care, but it's also making progress elsewhere. Johnson & Johnson has a robust underlying business, and a rare and ongoing dividend streak.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
3 Dividend Growth Stocks to Accumulate on Dips: August Edition
Dividend-paying stocks are ideal for outperforming the market or generating passive income. Finding dividend growth stocks, companies that have shown the ability and willingness to raise their distributions over time, providing consistent and growing income to investors, are even more valuable, particularly in this current market.
3 Defensive Stocks Weathering the Market Storm
In a week where fear, uncertainty, and widespread selling swept the market, three stocks stood out for their resilience: Johnson & Johnson NYSE: JNJ, Coca-Cola NYSE: KO, and Procter & Gamble NYSE: PG.
3 stocks to counter a recession, according to ChatGPT4-o
The most recent U.S. jobs report published on Friday, August 2, gave investors a fright, as evidenced by the massive bloodbath in both the stock market and across the cryptocurrency markets, with the flagship digital asset Bitcoin (BTC) now struggling to stay above $50,000.
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports, a Nature publication and the 5th most-cited journal in the world, according to the publisher. A link to the publication can be found HERE.
Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports, a Nature publication and the 5th most-cited journal in the world, according to the publisher. A link to the publication can be found HERE.
